Unable to promote its large inventory of Covid vaccine Sputnik Light amid the Russia-Ukraine battle, the Bengaluru-based Stelis Biopharma has written to Prime Minister Narendra Modi inquiring for for procurement of the jabs for inoculating electorate right here or supplying to different nations underneath the Vaccine Maitri programme. Stelis Biopharma, the biopharmaceutical arm of Strides Pharma Science, mentioned it would now not promote 2.5 crore gadgets of the single-dose vaccine manufactured via it because of a number of constraints following the Russian-Ukraine struggle.
The Drugs Controller General of India (DCGI) had granted emergency use permission to Sputnik Light, topic to sure regulatory provisions, in February this 12 months. However, it’s lately now not being administered within the nation. In the letter written on May 13, Arun Kumar, Founder and Director of Stelis Biopharma Limited, mentioned that once the high minister had asked the business to equipment as much as take on the pandemic, the company invested over Rs 700 crore to arrange a state-of the-art vaccine production facility inside of six months in spite of the COVID-19-induced restrictions and briefly commenced the manufacturing of Sputnik Light.The corporate additionally gained govt approvals to provide and export the jabs.
“We are proud to state that after having been granted due approvals by the Government of India, we started manufacturing Sputnik Light in India and produced no less than 2.5 crore vaccine doses. However, due to several constraints related to Russia, these vaccines are lying unsold with us at present,” Kumar mentioned. Kumar asked that the federal government will have to achieve the to be had doses, failing which those gets wasted and the corporate will face an enormous monetary loss. “We request the Government of India to procure our readily available vaccine and administer it to the people of India or donate it to other countries under the India Aid / Covid Maitri programme,” he mentioned. Sputnik Light is a one-dose vaccine and is similar as component-1 of Sputnik V. In March 2021, Stelis had partnered with Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, to provide and provide the vaccine.